BioSpace News Archive

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of a new analysis from the N-MOmentum clinical trial of UPLIZNA demonstrating the utility of a robust adjudication process that could improve clinical care decision-making in neuromyelitis optica spectrum disorder (NMOSD) through more accurate and consistent assessment of disease-related attacks.

SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, announced the appointment of Rohan Seth as Chief Financial Officer.

Masimo and Community Health System, based in Fresno, California, announced that CHS is adopting a variety of advanced Masimo monitoring technologies and solutions across its campuses.

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”) today announced that the Company received a Communication from the European Patent Office (EPO) regarding Cyclo Therapeutics’ European Patent Application No.19805439.7 titled, “Methods for Treating Alzheimer’s Disease.”

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”) announced today its submission of a 510(k) application to the U.S. Food and Drug Administration (FDA) for its OneRF™ Ablation System.

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, neuropsychiatric conditions, and ophthalmology, announced that the first subject was enrolled at University of California San Francisco Medical Center on June 9, 2023.

RenovoRx, Inc. announced that ROTH Capital will host a Key Opinion Leader webcast with Dr. Michael Pishvaian, Principal Investigator of the Phase III TIGeR-PaC clinical trial and Director of the Gastrointestinal, Developmental Therapeutics, and Clinical Research Programs at Johns Hopkins University.

Veracyte, Inc. announced that three abstracts highlighting new data on the company’s Afirma test and capabilities will be presented at ENDO 2023, the annual meeting of The Endocrine Society, which is taking place June 15-18 in Chicago, Ill.

Lantern Pharma Inc. (NASDAQ: LTRN) today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for LP-184, which is being developed for multiple advanced solid tumors and central nervous system (CNS) cancers.

Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a strong focus in oncology and rare diseases, announces the publication of real-world evidence of AKYNZEO® (fosnetupitant with palonosetron) injection/for injection in the journal Advances in Therapy.